Join to View Full Profile
1515 Holcombe Blvd Unit 1374U Texas Md Anderson Cancer Center, Hem/Onc DeptHouston, TX 77030
Phone+1 713-792-2830
Dr. Gao is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2010 - 2013
University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 2006 - 2010
University of Kansas School of MedicineClass of 2006
Certifications & Licensure
FL State Medical License 2021 - Present
TX State Medical License 2011 - 2027
AZ State Medical License 2023 - 2026
TN State Medical License 2023 - 2026
WA State Medical License 2023 - 2026
AL State Medical License 2023 - 2025
GA State Medical License 2023 - 2025
American Board of Internal Medicine Medical Oncology- Join now to see all
Clinical Trials
- Pemetrexed Disodium in Treating Patients With Previously Treated Metastatic Urothelial Cancer Start of enrollment: 2017 May 09
Publications & Presentations
PubMed
- Author Correction: Resolving tissue complexity by multimodal spatial omics modeling with MISO.Kyle Coleman, Amelia Schroeder, Melanie Loth, Daiwei Zhang, Jeong Hwan Park
Nature Methods. 2025-03-06 - 1 citationsResolving tissue complexity by multimodal spatial omics modeling with MISO.Kyle Coleman, Amelia Schroeder, Melanie Loth, Daiwei Zhang, Jeong Hwan Park
Nature Methods. 2025-03-01 - Author Correction: Resolving tissue complexity by multimodal spatial omics modeling with MISO.Kyle Coleman, Amelia Schroeder, Melanie Loth, Daiwei Zhang, Jeong Hwan Park
Nature Methods. 2025-03-01
Journal Articles
- Author Correction: Fecal Microbiota Transplantation for Refractory Immune Checkpoint Inhibitor-Associated ColitisMatthew T Campbell, Jennifer A Wargo, John R Stroehlein, Padmanee Sharma, Sumit K Subudhi, Gottumukkala S Raju, Jianjun Gao, Alexander J Lazar, Dipen M Maru, Michael T..., Nature
- Fecal Microbiota Transplantation for Refractory Immune Checkpoint Inhibitor-Associated ColitisJohn R Stroehlein, Sumit K Subudhi, Jennifer A Wargo, Dipen M Maru, Gottumukkala S Raju, Jianjun Gao, Matthew T Campbell, Michael T Tetzlaff, Padmanee Sharma, Nature
Lectures
- A pilot presurgical study evaluating anti-PD-L1 durvalumab (durva) plus anti-CTLA-4 tremelimumab (treme) in patients (pts) with high-risk muscle-invasive bladder carci...2019 ASCO Annual Meeting - 6/1/2019
- A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eli...2019 ASCO Annual Meeting - 6/1/2019
- A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eli...2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Press Mentions
MD Anderson Research Highlights for March 12, 2025March 12th, 2025- MD Anderson Research Highlights for January 22, 2025January 22nd, 2025
- Immunotherapy Clinical Trial Puts Stage IV Kidney Cancer into RemissionMarch 29th, 2023
- Join now to see all
Grant Support
- Molecular Mechanisms of Bladder Cancer ImmunometabolismUNIVERSITY OF TX MD ANDERSON CAN CTR2023–2028
- Decoding tumor metabolic and immunologic interactions driving racial disparity in African American patients with bladder cancer.BAYLOR COLLEGE OF MEDICINE2023–2028
- Decoding tumor metabolic and immunologic interactions driving racial disparity in African American patients with bladder cancer.BAYLOR COLLEGE OF MEDICINE2023–2028
- Effective combination therapy for MTAP-deficient bladder carcinoma by targeting metabolic vulnerability and modulating tumor immune microenvironmentUNIVERSITY OF TX MD ANDERSON CAN CTR2021–2026
- Effective combination therapy for MTAP-deficient bladder carcinoma by targeting metabolic vulnerability and modulating tumor immune microenvironmentUNIVERSITY OF TX MD ANDERSON CAN CTR2021–2026
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
